Compare BGLC & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGLC | XAIR |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.4M |
| IPO Year | 2019 | 2015 |
| Metric | BGLC | XAIR |
|---|---|---|
| Price | $2.14 | $0.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 2.1K | ★ 343.5K |
| Earning Date | 04-14-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.78 | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,424,911.00 | $3,705,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $1.92 | $0.15 |
| 52 Week High | $15.19 | $3.78 |
| Indicator | BGLC | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 33.95 |
| Support Level | $2.14 | $0.43 |
| Resistance Level | $2.73 | $0.82 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 15.35 |
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.